Instead, the higher the frequency of RSV-specific CD8+ T cells in baseline BAL, the lower the cumulative symptom score (Spearman's r=−0.691, P=0.0142; Fig. 9c) and the lower the cumulative viral load (Spearman's r=−0.668, P=0.0317; Fig. 9d) in those who subsequently developed PCR+ infection. This evidence concerns the gene CD8A and infection.